Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
- A Personal Essay: My Experiences in the Pharmaceutical Industry - Adventures in Medicinal ChemistryA Career in Drug Discovery - Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAA and NMDA Receptors - Development of LRRK2 Kinase Inhibitors for Parkinson's Disease - Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders - Small Molecule Modulators of GPR40 (FFA1) - Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents - Current Approaches to the Treatment of Atrial Fibrillation - Advances in the Discovery of Small Molecule IRAK4 Inhibitors - H4 Receptor Antagonists and Their Potential Therapeutic Applications - Urate Crystal Deposition Disease and Gout
New Therapies for an Old Problem - p53
MDM2 and MDMX Antagonists - Modulators of Atypical Protein Kinase C as Anticancer Agents - Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis - Nucleosides and Nucleotides for the Treatment of Viral Diseases - Advances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial Agents - Tumor Microenvironment as Target in Cancer Therapy - Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs) - Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications - Disease Modifying Agents for the Treatment of Cystic Fibrosis - Advancements in Stapled Peptide Drug Discovery and Development - Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development - Case History: ForxigaTM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes - Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation - Case History: XeljanzTM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis - New Chemical Entities Entering Phase III Trials in 2013 - To Market, To Market
2013
